- Home
- FATE vs IKT Comparison
FATE vs IKT Comparison
Compare FATE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- IKT
- Stock Information
- Founded
- FATE 2007
- IKT 2008
- Country
- FATE United States
- IKT United States
- Employees
- FATE N/A
- IKT N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- IKT Health Care
- Exchange
- FATE Nasdaq
- IKT Nasdaq
- Market Cap
- FATE 108.2M
- IKT 167.2M
- IPO Year
- FATE 2013
- IKT 2020
- Fundamental
- Price
- FATE $0.94
- IKT $2.20
- Analyst Decision
- FATE Hold
- IKT Buy
- Analyst Count
- FATE 9
- IKT 2
- Target Price
- FATE $5.50
- IKT $8.00
- AVG Volume (30 Days)
- FATE 3.4M
- IKT 167.2K
- Earning Date
- FATE 03-05-2025
- IKT 03-26-2025
- Dividend Yield
- FATE N/A
- IKT N/A
- EPS Growth
- FATE N/A
- IKT N/A
- EPS
- FATE N/A
- IKT N/A
- Revenue
- FATE $13,631,000.00
- IKT $1.00
- Revenue This Year
- FATE N/A
- IKT N/A
- Revenue Next Year
- FATE N/A
- IKT N/A
- P/E Ratio
- FATE N/A
- IKT N/A
- Revenue Growth
- FATE N/A
- IKT N/A
- 52 Week Low
- FATE $0.87
- IKT $1.12
- 52 Week High
- FATE $7.70
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- FATE 37.74
- IKT 45.02
- Support Level
- FATE $0.87
- IKT $1.91
- Resistance Level
- FATE $1.03
- IKT $2.22
- Average True Range (ATR)
- FATE 0.12
- IKT 0.25
- MACD
- FATE -0.01
- IKT -0.01
- Stochastic Oscillator
- FATE 13.12
- IKT 29.59
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.